<DOC>
	<DOCNO>NCT02567552</DOCNO>
	<brief_summary>Study endometrial predecidualization use subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50 mg/day , determine whether difference endometrial transformation endometrial receptivity .</brief_summary>
	<brief_title>Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone</brief_title>
	<detailed_description>The aim study compare predecidualization endometrial receptivity gene expression use subcutaneous progesterone 25 mg/day versus intramuscular progesterone 50 mg/day healthy woman childbearing age . Both , two drug dos administer clinical trial , routine clinical practice . A controlled ovarian stimulation previously perform follow routine clinical practice 10-12 day standard dos subcutaneous FSH 150-225 IU/day , accord BMI number antral follicle . A GnRH antagonist shall administer , initiate accord donor 's follicular growth great equal14 mm diameter follicle . Final maturation shall perform bolus GnRH agonist exist least 3 follicle great equal17 mm diameter , therefore perform follicular puncture 36 hour bolus agonist administer . If donor meet inclusion criterion , inform study , agree , sign inform consent . Randomization shall perform 2 arm ; arm 1 administer subcutaneous progesterone 25 mg/day ( Prolutex ; Angelini , Spain ) , arm 2 , intramuscular progesterone 50 mg/day ( Prontogest IBSA , Italy ) . In arm 12 donor ( ITT population ) include . The randomization treatment group shall perform day follicular puncture program . To purpose , randomize consecutive sampling use mean assignment table . The medication administer person involved assessment responsible group assignment , data centralization drug assignment . At day 5 ( 5 day follicular puncture ) : endometrial thickness measurement mean transvaginal ultrasound perform endometrial biopsy take two sample : 1 sample Anatomical Pathology 1 sample Endometrial Receptivity Array ( ERA ) .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Female age 18 34 year BMI 18 28 kg/m2 Endometrial thickness &gt; 7 mm day progesterone treatment initiation ( day follicular puncture ) Follicular maturation single bolus GnRH agonist Egg donor undergo cycle ovarian stimulation IVI Barcelona Centre Egg donor select accordance requirement Law 14/2006 26 May 2006 Assisted Human Reproduction Techniques Informed consent sign date Known allergy progesterone formulation excipients Known allergy estrogen Known thrombophilias Alcohol , drug psychotropic medication dependence Concurrent participation another study Concomitant medication may interfere study medication ovarian stimulation Failure comply requirement egg donor accordance Law 14/2006 26 May 2006 Assisted Human Reproduction Techniques</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>endometrial receptivity</keyword>
	<keyword>endometrial predecidualization</keyword>
	<keyword>endometrial genomics</keyword>
	<keyword>endometrial receptivity array</keyword>
</DOC>